Literature DB >> 32360833

Therapeutic potential of nicotinamide adenine dinucleotide (NAD).

Marta Arenas-Jal1, J M Suñé-Negre2, Encarna García-Montoya2.   

Abstract

Nicotinamide adenine nucleotide (NAD) is a small ubiquitous hydrophilic cofactor that participates in several aspects of cellular metabolism. As a coenzyme it has an essential role in the regulation of energetic metabolism, but it is also a cosubstrate for enzymes that regulate fundamental biological processes such as transcriptional regulation, signaling and DNA repairing among others. The fluctuation and oxidative state of NAD levels regulate the activity of these enzymes, which is translated into marked effects on cellular function. While alterations in NAD homeostasis are a common feature of different conditions and age-associated diseases, in general, increased NAD levels have been associated with beneficial health effects. Due to its therapeutic potential, the interest in this molecule has been renewed, and the regulation of NAD metabolism has become an attractive target for drug discovery. In fact, different approaches to replenish or increase NAD levels have been tested, including enhancement of biosynthesis and inhibition of NAD breakdown. Despite further research is needed, this review provides an overview and update on NAD metabolism, including the therapeutic potential of its regulation, as well as pharmacokinetics, safety, precautions and formulation challenges of NAD supplementation.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug discovery; Metabolism; NAD; Supplementation; Therapeutic potential

Mesh:

Substances:

Year:  2020        PMID: 32360833     DOI: 10.1016/j.ejphar.2020.173158

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Identification of a novel homozygous mutation in NAXE gene associated with early-onset progressive encephalopathy by whole-exome sequencing: in silico protein structure characterization, molecular docking, and dynamic simulation.

Authors:  Marwa Maalej; Lamia Sfaihi; Marwa Ammar; Fakher Frikha; Marwa Kharrat; Olfa Alila-Fersi; Emna Mkaouar-Rebai; Abdelaziz Tlili; Thouraya Kammoun; Faiza Fakhfakh
Journal:  Neurogenetics       Date:  2022-07-11       Impact factor: 3.017

2.  CD38 Enhances TLR9 Expression and Activates NLRP3 Inflammasome after Porcine Parvovirus Infection.

Authors:  Yi Zheng; Yixuan Xu; Weimin Xu; Sanjie Cao; Qigui Yan; Xiaobo Huang; Yiping Wen; Qin Zhao; Senyan Du; Yifei Lang; Shan Zhao; Rui Wu
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.